Eylward Susan sold $4K of IMNN

Imunon (IMNN) held its Q2 2026 earnings call. Management reported Phase 2 OVATION II median overall survival of 45.1 months vs 30.4 months, and PARP maintenance survival of 65.6 vs 41.4 months. Q2 R&D was $1.5M, G&A $1.3M, net loss $2.8M. Cash was $6.9M after a $10M financing.

IMUNON (IMNN) reported Q2 2026 results and an update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 for newly diagnosed advanced ovarian cancer. The company said enrollment is progressing faster than expected and expects completion in 1H 2029. It cited Phase 2 OVATION 2 median OS of 45.1 vs 30.4 months and MRD/ctDNA clearance improvements. Net loss was $2.8M.

Imunon, Inc. (IMNN) said its OVATION 3 Phase III enrollment is ahead of plan and that IMNN-001 has strong safety and efficacy data, according to an Aug. 11, 2026 Q2 2026 audio transcript. The company reported stable financials and a $10 million financing to extend its runway through year-end 2026.

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enroll

Imunon Inc. (NASDAQ:IMNN) updated its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said site activation and enrollment are ahead of forecasts, with full enrollment expected by Q2 2029. It reported no cytokine release syndrome or serious immune-related adverse events and noted two interim analyses that could support an early BLA. Shares rose 1.95% to $1.57 premarket.

IMUNON (Nasdaq: IMNN) provided an update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said enrollment is ahead of plan, with a study rate of about 0.5 patients per site per month versus 0.3 planned, and it now expects completion in Q2 2029. It reported no cytokine release syndrome and comparable safety versus control.